Literature DB >> 15015631

Selective depletion of the allo-antigen specific T cells by Fas/FasL pathway by cytokine IFN-gamma and IL-2.

Juan Xiao1, Ping Zou, Zhongwen Liu, Lingbo Liu, Zhongbo Hu.   

Abstract

To investigate the value of apoptosis of the allo-antigen specific T cells induced by Fas/FasL pathway in preventing graft-versus-host disease (GVHD), the CD34+ cells transfected with FasL or not, used as stimulus cells, were mixed with allo-antigen specific T lymphocytes in presence or absence of IFN-gamma and IL-2. After 5 days, apoptosis of T cells was detected by TdT nick end mediated dUTP labeling (TUNEL) and flow cytometry (FCM). The affects of these two cytokines on CD34+ cells in the graft were also compared. The ratio of apoptosis of T cells was 12.1+/-1.5% when CD34+ cells transfected with FasL was used as stimulus cells, much higher than that of CD34+ cells non-transfected (3.2+/-1.1%, P<0.01). And in presence of IFN-gamma or IL-2, the ratio reached 20.1+/-2.3%, 17.6+/-1.3% respectively (P<0.01). However, IFN-gamma up-regulated Fas expression of CD34+ cells and increased the sensibility of CD34+ cells to soluble FasL (sFasL); IL-2 showed no such effect. It is possible to induce apoptosis of the allo-antigen specific T cells of grafts activated by allo-antigen by exogenous Fas ligand expressed on recipient cells and this might provide a new approach for preventing GVHD and IL-2 may be more suitable for clinical application.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15015631     DOI: 10.1007/BF02829413

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  8 in total

1.  Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.

Authors:  H T Lau; M Yu; A Fontana; C J Stoeckert
Journal:  Science       Date:  1996-07-05       Impact factor: 47.728

Review 2.  T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.

Authors:  R Champlin
Journal:  Hematol Oncol Clin North Am       Date:  1990-06       Impact factor: 3.722

3.  The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease.

Authors:  Y Kataoka; T Iwasaki; T Kuroiwa; Y Seto; N Iwata; N Hashimoto; A Ogata; T Hamano; E Kakishita
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

4.  Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease.

Authors:  M R van den Brink; E Moore; K J Horndasch; J M Crawford; G F Murphy; S J Burakoff
Journal:  Transplantation       Date:  2000-07-15       Impact factor: 4.939

Review 5.  Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction.

Authors:  H J Deeg
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

6.  Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome.

Authors:  H J Deeg; C Beckham; M R Loken; E Bryant; M Lesnikova; H M Shulman; T Gooley
Journal:  Leuk Lymphoma       Date:  2000-04

7.  CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells.

Authors:  K Stahnke; S Hecker; E Kohne; K M Debatin
Journal:  Exp Hematol       Date:  1998-08       Impact factor: 3.084

8.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

  8 in total
  1 in total

1.  Apoptotic bone marrow CD34+ cells in cirrhotic patients.

Authors:  Shuang-Suo Dang; Wen-Jun Wang; Ning Gao; Shun-Da Wang; Mei Li; La-Yang Liu; Ming-Zhun Sun; Tao Dong
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.